Gilead Sciences Inc. closed $6.85 short of its 52-week high ($98.90), which the company achieved on November 11th.

The CHMP recommends the approval of Gilead's seladelpar in combination with ursodeoxycholic acid for the treatment of primary ...

Gilead (GILD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,075.53 today based on a ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

UK-based NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announced the appointment of Michael ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Repare Therapeutics (RPTX – Research Report), with a ...

After a median follow-up of 9.6 years, irradiated patients had a 10-year overall survival (OS) of 81.4% versus 82% for those ...

The broad U.S. stock market posted solid gains that saw a reversal of trends from the first half of the year. Click here to read the full commentary.

New research suggests that activation of the PPARδ protein, which is linked to inflammation, could treat or prevent diabetic cardiomyopathy, a serious heart condition.

Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal.